Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 19, 2019

http://api.tenkwizard.com/cgi/image?quest=1&rid=23&ipage=12974163&doc=2
Biogen Inc.
(Exact name of registrant as specified in its charter)
Delaware
0-19311
33-0112644
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

225 Binney Street, Cambridge, Massachusetts 02142
(Address of principal executive offices; Zip Code)
    
Registrant’s telephone number, including area code: (617) 679-2000
Not Applicable
(Former name or former address, if changed since last report.)
    
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
BIIB
Nasdaq

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

¨ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨










Item 5.07     Submission of Matters to a Vote of Security Holders

On June 19, 2019, Biogen Inc. (the "Company") held its 2019 Annual Meeting of Stockholders. The final voting results for this meeting are as follows:

1.
Stockholders elected thirteen nominees to the Board of Directors to serve for a one-year term extending until the 2020 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows:
Nominee
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
Alexander J. Denner
 
135,933,823

 
16,122,991

 
303,436

 
14,580,602

Caroline D. Dorsa
 
133,190,430

 
18,770,818

 
399,002

 
14,580,602

William A. Hawkins
 
137,141,697

 
14,803,826

 
414,727

 
14,580,602

Nancy L. Leaming
 
135,824,166

 
16,139,930

 
396,154

 
14,580,602

Jesus B. Mantas
 
137,145,985

 
14,801,290

 
412,975

 
14,580,602

Richard C. Mulligan
 
136,644,662

 
15,318,056

 
397,532

 
14,580,602

Robert W. Pangia
 
132,077,121

 
19,986,742

 
296,387

 
14,580,602

Stelios Papadopoulos
 
128,365,470

 
22,256,627

 
1,738,153

 
14,580,602

Brian S. Posner
 
135,920,134

 
16,028,261

 
411,855

 
14,580,602

Eric K. Rowinsky
 
134,686,251

 
17,270,334

 
403,665

 
14,580,602

Lynn Schenk
 
133,996,216

 
18,074,284

 
289,750

 
14,580,602

Stephen A. Sherwin
 
135,333,660

 
16,611,925

 
414,665

 
14,580,602

Michel Vounatsos
 
136,835,714

 
15,113,557

 
410,979

 
14,580,602

  

2.
Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019, with the votes cast as follows:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
164,405,880
 
2,159,974
 
374,998
 


3.
Stockholders approved the advisory vote on executive compensation, with the votes cast as follows:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
140,932,942
 
11,086,464
 
340,844
 
14,580,602
 









Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Biogen Inc.
By: /s/ James Basta
James Basta
Chief Corporation Counsel and Assistant Secretary
Date: June 20, 2019